Evaluation on the Safety and Efficacy of Tirofiban in Patients with Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention

Objective To evaluate the safety and efficacy of tirofiban in patients with acute ST elevation myocardial infarction(STEMT) treated by primary percntaneous coronary intervention(PCI).Methods 58 STEMT patients were ran- domly divided into two groups:30 patients in tirofiban group and 28 in control group.All the individuals were performed PCI with 12 hours after onset of AMI.Immediately after PCI,all the individuals of tirofiban group were intravenously admin- istered tirofiban (0.15μg/kg·min~(-1)) following a loading dose in 30 rains (0.4μg/kg·min~(-1)).All the individuals were intravenously administered heparin 8 000～10 000 u during PCI and clopidogrel 75 mg perday and aspirin 75 mg per day af- ter PCI.Thrombolysis in acute myocardial infarction(TIMI) grade was studied before and after PCI.The major adverse car- diac events(MACE) in 4 weeks and bleeding complications were studied.Results In tirofiban group,the occurrence of slow-reflow and MACE at 4 weeks were significantly lower than those in control group.The oecurance of bleeding complica- tion in tirofiban group was higher than those in control group,but there was no significant difference in both groups.Con- clusion Application of tirofiban during primary PCI in patients with AMI was safe and effective,which may reduce the oc- currence of MACE and improve TIMI flow of the infarction related artery(IRA) in patients with AMI during primary PCI.